BTK and B-cell non-Hodgkin lymphoma: Inventing more novel agents with differential mechanisms or synergistically combining BTK inhibitors with other chemotherapy, antibodies, targeted agents, or immunotherapy may open the way for a cure in B-cell lymphomas.